tbuckley/cabot-search huggingface dataset:
Biomarker analyses from the phase 3 randomized CLEAR trial: Lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma
Authors: R J Motzer, C Porta, M Eto, T E Hutson, S Y Rha, J R Merchan, E Winquist, H Gurney, V Grünwald, S George, J Markensohn, J E Burgents, R Cristescu, P Sachdev, Y Narita, J Huang, Z Zhao, C E Okpara, Y Minoshima, T K Choueiri
Journal: Annals of Oncology (2024)

In CLEAR, lenvatinib + pembrolizumab (L+P) significantly improved efficacy versus sunitinib in first-line treatment of patients with advanced renal cell carcinoma (RCC). We report results from CLEAR biomarker analyses. PD-L1 immunohistochemistry (IHC) and next-generation sequencing assays (whole exome sequencing/RNA-sequencing) were performed on archival tumor specimens. For IHC-derived/RNA-sequencing analyses, a continuous analysis was performed adjusting by Karnofsky performance status (KPS) score for: PD-L1 CPS versus best overall response (BOR)/PFS; and each gene-signature score (T-cell inflamed gene-expression profile [TcellinfGEP]/non-TcellinfGEP signatures including proliferation and angiogenesis) versus BOR/PFS. Association between mutation status of RCC driver genes and PFS were analyzed for genes for which ≥20 patients per arm had oncogenic alterations. Association of molecular subtypes with outcome was evaluated with baseline KPS adjustments. The set of biomarkers evaluated and statistical significance criteria for PD-L1 CPS, gene signature scores, and molecular subtypes were pre-specified. Within-arm analyses using continuous values showed no association between PD-L1 levels and BOR/PFS for either treatment. PFS hazard ratios between arms were similar regardless of mutant or wildtype subgroups of RCC driver genes (VHL, PBRM1, SETD2, BAP1, KDM5C). No associations between PFS and gene-signature scores were observed for L+P. With sunitinib, high proliferation and MYC signature scores showed shorter PFS; high angiogenesis and microvessel density signature scores showed longer PFS. Six new molecular subtypes were defined. Tumors of patients with favorable/intermediate risk were enriched in angiogenesis and angiogenesis/stromal clusters; those with poor risk were enriched in proliferative and unclassified (low-TcellinfGEP/low-angiogenesis/low-proliferation) clusters. No association between molecular subtypes and PFS for L+P/sunitinib was observed (after adjustment for KPS and gene signatures that were individually associated with PFS). Improvements in ORR and PFS for L+P versus sunitinib in aRCC were observed consistently across a range of biomarker subgroups defined using RCC driver mutations, PD-L1, gene expression signatures, and molecular subtypes.
Genomic correlates of response and resistance to the irreversible FGFR1-4 inhibitor futibatinib based on biopsy and circulating tumor DNA profiling
Authors: L Goyal, D DiToro, A Hollebecque, J A Bridgewater, M Shimura, A Kano, S Okamura, J L Silhavy, V Wacheck, A Halim, F Meric-Bernstam
Journal: Annals of Oncology (2024)
Successful Treatment of Mogamulizumab-Associated Rash With Upadacitinib
Authors: Daniel Martín-Torregrosa, Ignacio Torres-Navarro, Miguel Mansilla-Polo, Fernando Navarro-Blanco, Blanca de Unamuno-Bustos, Vicent Martínez I. Cózar, Rafael Botella-Estrada
Journal: JAMA Dermatology (2024)

This case report describes 2 older patients with refractory mogamulizumab-associated rash successfully treated with upadacitinib.
Private Equity Ownership of US Opioid Treatment Programs
Authors: David T. Zhu, Zirui Song, Sneha Kannan, Christopher L. Cai, Simar S. Bajaj, Suhas Gondi
Journal: JAMA Psychiatry (2024)

This cross-sectional study assesses acquisitions of US opioid treatment programs by private equity firms overall and at the zip-code level.
rest, like a river
Authors: Leena Danawala
Journal: JAMA (2024)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors JAMA+ AI Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Ivonescimab Plus Chemotherapy in Patients With <i>EGFR</i> Variant Non–Small Cell Lung Cancer
Authors: Zaoqu Liu, Dan Shan, Xinwei Han
Journal: JAMA (2024)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors JAMA+ AI Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Anesthetic Agents Are Not Harmful During Pregnancy—Reply
Authors: Tiffany A. Glazer, Micah T. Long
Journal: JAMA Surgery (2024)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast JAMA+ AI Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Misapplication of Biologic Mesh in Clean-Site Elective Ventral Hernia Repair
Authors: John C. Alverdy
Journal: JAMA Surgery (2024)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast JAMA+ AI Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2025 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Medical research agency: 5 years of reshaping the clinical trials ecosystem in Poland
Authors: Diana Kitala, Katarzyna Kaczmarska, Joanna Kornacka, Krzysztof Górski, Elżbieta Bylina, Karolina Nowak, Rafał Staszewski, Zuzanna Nowak-Życzyńska, Wojciech Fendler
Journal: The Lancet Regional Health - Europe (2024)
Copper–luteolin nanocomplexes for Mediating multifaceted regulation of oxidative stress, intestinal barrier, and gut microbiota in inflammatory bowel disease
Authors: Wanyue Fu, Zhongshi Huang, Weiqi Li, Lingling Xu, Miaomiao Yang, Yan Ma, Hanghang Liu, Haisheng Qian, Wanni Wang
Journal: Bioactive Materials (2024)
Buprenorphine Injection Among Rural Persons Who Inject Drugs
Authors: Kaitlin A. Zinsli, Elenore P. Bhatraju, Judith Feinberg, Thomas J. Stopka, Peter D. Friedmann, William Zule, Hannah L. F. Cooper, April M. Young, P. Todd Korthuis, Mai T. Pho, Wiley D. Jenkins, William C. Miller, Vivian F. Go, David W. Seal, Ryan P. Westergaard, Rob J. Fredericksen, Joseph A. Delaney, Judith I. Tsui
Journal: JAMA Network Open (2024)

This cross-sectional study investigates buprenorphine injection, including factors associated with this use, among rural individuals who inject drugs.
Ivonescimab Plus Chemotherapy in Patients With EGFR Variant Non–Small Cell Lung Cancer—Reply
Authors: Wenfeng Fang, Wenting Li, Li Zhang
Journal: JAMA (2024)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors JAMA+ AI Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Time‐restricted versus standard‐duration immunosuppression after allogeneic hematopoietic stem cell transplantation: Results of the prospective randomized HOVON‐96 trial
Authors: Annoek E. C. Broers, Ellen Meijer, Bronno van der Holt, Cornelis N. de Jong, Erfan Nur, Geerte L. van Sluis, Goda Choi, Michel van Gelder, Johan A. Maertens, Jürgen Kuball, Dries Deeren, Heleen A. Visser‐Wisselaar, Lamberdina A. H. M. Meulendijks, Jan J. Cornelissen
Journal: HemaSphere (2024)

Cyclosporine A combined with mycophenolate mofetil (CsA/MMF) has become an established regimen for the prevention of graft-versus-host disease (GVHD) following non-myeloablative (NMA) allogeneic hematopoietic stem cell transplantation (alloHSCT). However, the optimal duration of immunosuppression (IS) has not yet been defined and overtreatment is of concern. We hypothesized that time-restricted IS with CsA/MMF would increase the proportion of patients with non-severe GVHD compared to standard-duration IS, thereby resulting in reduction of the relapse rate and improvement of progression-free survival (PFS) and overall survival (OS). In a prospective randomized, multicenter, phase III trial, patients were allocated (1:1) to standard or time-restricted IS. A total of 389 patients were randomized, of whom 369 were transplanted (184 vs. 185 patients). The primary endpoint, the proportion of patients with non-severe GVHD defined as acute GVHD grades I-II without gut involvement or chronic GVHD not requiring systemic treatment within 180 days posttransplant, was 23% after standard-duration IS versus 24% after time-restricted IS (odds ratio: 1.02; 95% confidence interval (CI) 0.63-1.66,
Ivonescimab Plus Chemotherapy in Patients With <i>EGFR</i> Variant Non–Small Cell Lung Cancer
Authors: Wen-Chien Cheng, Guosheng Wang, Qi Mei
Journal: JAMA (2024)

To the Editor We are writing to express some concerns about the methodology and interpretation of a recent study by Feng et al about treatment of pretreated epidermal growth factor receptor (EGFR)–variant non–small cell lung cancer (NSCLC).1
Intensive Glucose Lowering and Its Effects on Vascular Events and Death According to Age at Diagnosis and Duration of Diabetes: The ADVANCE Trial
Authors: Toshiaki Ohkuma, Katie Harris, Mark Woodward, Pavel Hamet, Stephen Harrap, Giuseppe Mancia, Michel Marre, Neil Poulter, John Chalmers, Sophia Zoungas
Journal: Diabetes Care (2024)

To compare the vascular effects of pursuing more versus less glucose lowering in patients with younger or older age at diabetes diagnosis, and with shorter or longer diabetes duration.
scTrends: A living review of commercial single-cell and spatial 'omic technologies
Authors: Joachim De Jonghe, James W Opzoomer, Amaia Vilas-Zornoza, Benedikt S Nilges, Peter Crane, Marco Vicari, Hower Lee, David Lara-Astiaso, Torsten Gross, Jörg Morf, Kim Schneider, Juliana Cudini, Lorenzo Ramos-Mucci, Dylan Mooijman, Katarína Tiklová, Sergio Marco Salas, Christoffer Mattsson Langseth, Nachiket D Kashikar, Denis Schapiro, Joakim Lundeberg, Mats Nilsson, Alex K Shalek, Adam P Cribbs, Jake P Taylor-King
Journal: Cell Genomics (2024)

Understanding the rapidly evolving landscape of single-cell and spatial omic technologies is crucial for advancing biomedical research and drug development. We provide a living review of both mature and emerging commercial platforms, highlighting key methodologies and trends shaping the field. This review spans from foundational single-cell technologies such as microfluidics and plate-based methods to newer approaches like combinatorial indexing; on the spatial side, we consider next-generation sequencing and imaging-based spatial transcriptomics. Finally, we highlight emerging methodologies that may fundamentally expand the scope for data generation within pharmaceutical research, creating opportunities to discover and validate novel drug mechanisms. Overall, this review serves as a critical resource for navigating the commercialization and application of single-cell and spatial omic technologies in pharmaceutical and academic research.
Effects of gene dosage on cognitive ability: A function-based association study across brain and non-brain processes
Authors: Guillaume Huguet, Thomas Renne, Cécile Poulain, Alma Dubuc, Kuldeep Kumar, Sayeh Kazem, Worrawat Engchuan, Omar Shanta, Elise Douard, Catherine Proulx, Martineau Jean-Louis, Zohra Saci, Josephine Mollon, Laura M Schultz, Emma E M Knowles, Simon R Cox, David Porteous, Gail Davies, Paul Redmond, Sarah E Harris, Gunter Schumann, Guillaume Dumas, Aurélie Labbe, Zdenka Pausova, Tomas Paus, Stephen W Scherer, Jonathan Sebat, Laura Almasy, David C Glahn, Sébastien Jacquemont
Journal: Cell Genomics (2024)
Delayed Mortality in Patients Receiving Postoperative High-Acuity Care
Authors: Guy Ludbrook, Esrom E. Leaman, Michael P. W. Grocott, Colin Royse, Jamie Sleigh, Sandy Clarke-Errey, L. Bogdan Solomon
Journal: JAMA Surgery (2024)

This cohort study compares longer-term postsurgical mortality after advanced recovery room care compared with usual ward care.
Recent Patterns and Trends in Global Prostate Cancer Incidence and Mortality: An Update
Authors: Elizabeth J Schafer, Mathieu Laversanne, Hyuna Sung, Isabelle Soerjomataram, Alberto Briganti, William Dahut, Freddie Bray, Ahmedin Jemal
Journal: European Urology (2024)

Our aim was to examine worldwide patterns and trends for prostate cancer (PC) incidence and mortality using high-quality, up-to-date, population-based data.
Selective vs Routine Cholangiography Across a Health Care Enterprise
Authors: Evelyn V. Alexander, Nicholas Galouzis, Taylor S. Riall
Journal: JAMA Surgery (2024)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast JAMA+ AI Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Injury to Internal Thoracic Artery to Left Anterior Descending Artery Grafts in Cardiac Reoperations
Authors: Joshua E. Insler, Richard A. E. Ramsingh, Jules J. Bakhos, Penny L. Houghtaling, Marijan Koprivanac, Lars G. Svensson, Eugene H. Blackstone, Faisal G. Bakaeen
Journal: JAMA Surgery (2024)

This case series examines experiences and outcomes associated cardiac reoperations with preexisting internal thoracic artery to left anterior descending artery grafts.
BEEx is An Open-Source Tool that Evaluates Batch Effects in Medical Images to Enable Multi-center Studies
Authors: Yuxin Wu, Xiongjun Xu, Yuan Cheng, Xiuming Zhang, Fanxi Liu, Zhenhui Li, Lei Hu, Anant Madabhushi, Peng Gao, Zaiyi Liu, Cheng Lu
Journal: Cancer Research (2024)

The batch effect is a nonbiological variation that arises from technical differences across different batches of data during the data generation process for acquisition-related reasons, such as collection of images at different sites or using different scanners. This phenomenon can affect the robustness and generalizability of computational pathology- or radiology-based cancer diagnostic models, especially in multi-center studies. To address this issue, we developed an open-source platform, Batch Effect Explorer (BEEx), that is designed to qualitatively and quantitatively determine whether batch effects exist among medical image datasets from different sites. A suite of tools was incorporated into BEEx that provide visualization and quantitative metrics based on intensity, gradient, and texture features to allow users to determine whether there are any image variables or combinations of variables that can distinguish datasets from different sites in an unsupervised manner. BEEx was designed to support various medical imaging techniques, including microscopy and radiology. Four use cases clearly demonstrated the ability of BEEx to identify batch effects and validated the effectiveness of rectification methods for batch effect reduction. Overall, BEEx is a scalable and versatile framework designed to read, process, and analyze a wide range of medical images to facilitate the identification and mitigation of batch effects, which can enhance the reliability and validity of image-based studies.
A Phase 1 Study of FHD-609, a Heterobifunctional Degrader of Bromodomain-Containing Protein 9, in Patients With Advanced Synovial Sarcoma or SMARCB1-Deficient Tumors
Authors: J. Andrew Livingston, Jean-Yves Blay, Jonathan Trent, Claudia Valverde, Mark Agulnik, Mrinal Gounder, Axel Le Cesne, Meredith McKean, Michael J. Wagner, Silvia Stacchiotti, Samuel Agresta, Alfonso Quintás-Cardama, Sarah A. Reilly, Kathleen Healy, Denice Hickman, Tina Zhao, Alex Ballesteros-Perez, Alexis Khalil, Michael P. Collins, Jessica Piel, Kim Horrigan, Ariel Lefkovith, Scott Innis, Alexander J. Lazar, Gregory M. Cote, Andrew J. Wagner
Journal: Clinical Cancer Research (2024)

FHD-609, a potent, selective, heterobifunctional degrader of bromodomain-containing protein 9 (BRD9), was evaluated for treatment of patients with advanced synovial sarcoma (SS) or SMARCB1-deficient tumors.
How did the RCP get into a mess over physician associates?
Authors: Adele Waters
Journal: BMJ (2024)

The Royal College of Physicians has been at the centre of the UK row over physician associates. Adele Waters explores what happened and where it leaves the college now In March 2024 the Royal College of Physicians was forced to hold an extraordinary general meeting (EGM), only the third in its more than 500 year history.1 The issue that prompted it was physician associates (PAs), specifically their regulation, scope of practice, and expansion across the health service. The meeting was ill tempered and fraught, with participants describing it as "really aggressive" and an "unmitigated disaster."2 Such was the concern about the meeting's conduct and the level of hostility in the room that the RCP was forced to admit it had failed its membership and ordered an independent review to establish what had gone wrong.3 That review, carried out by the health think tank the King's Fund and published in September,2 found a "pervasive lack of trust and confidence" in the RCP's governance and that its governing council had been operating ineffectively. After the EGM the college saw several high level resignations: its former president Sarah Clarke,4 registrar Cathryn Edwards,5 former deputy registrar Jamie Read,6 and, after the King's Fund review, the chair of the board of trustees, David Croisdale-Appleby.7 In 2015 the college had established the Faculty of Physician Associates (FPA), in conjunction with Health Education England (as it was then called) and other medical royal colleges (box 1). Several members of the FPA's board also resigned en masse after the EGM, including its president and vice president.8 The FPA will close at the end of this year, although the RCP will continue to oversee the annual PA exam. Box 1 ### Timeline—RCP and PAsRETURN TO TEXT
Intraindividual Variability in Serial Lipoprotein(a) Concentrations Among Placebo-Treated Patients in the OCEAN(a)-DOSE Trial
Authors: Prakriti Gaba, Robert S Rosenson, J Antonio G López, Gerald F Watts, Thorsten M Leucker, Julia F Kuder, KyungAh Im, Helina Kassahun, Huei Wang, You Wu, Jingying Wang, E Magnus Ohman, Marc S Sabatine, Michelle L O'Donoghue
Journal: Journal of the American College of Cardiology (2024)